‘A Game Changer:’ Cures 2.0 Would Provide $11bn In ‘Subscription’ Contracts For New Antibiotics

The PASTEUR Act would delink some of an antibiotic’s revenue from prescription sales, with the goal of revitalizing the antibiotic pipeline with additional private investment while encouraging good public health stewardship of critically needed medicines.

Pulling a sled at the capitol (Nielsen Hobbs; the Pink Sheet |Alamy, Shutterstock images)
New “pull incentive” program to address antimicrobial resistance included in Cures 2.0 legislative package • Source: Nielsen Hobbs; the Pink Sheet |Alamy, Shutterstock images

The weak market for antimicrobials could be revived by a new $11bn US government-funded plan embedded in the draft Cures 2.0 legislation that would guarantee revenue for certain treatments regardless of the number of prescriptions sold.

Supporters of the plan, the bipartisan PASTEUR Act, believe the measure would lead to a new wave of private investment in the

More from Legislation

More from Pink Sheet

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By 

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.